STING1 and tuberculosis: Unlike FDA-approved PDE inhibitors, which showed poor performance against bacterial orthologs, these natural products represent promising scaffolds for developing novel anti-tuberculosis therapeutics that could enhance host STING-mediated immune responses without exerting selective pressure that promotes antimicrobial resistance.